Mass screening is a seductive lie. We have been conditioned to believe that finding cancer "early" is the undisputed gold standard of modern medicine. When news broke regarding the NHS trials of multi-cancer early detection (MCED) blood tests, the media reacted with the predictable, breathless enthusiasm of a tech startup at a seed funding round. They called it a "holy grail." They promised "genuine hope."
They are wrong.
The push for universal liquid biopsies—tests that detect circulating tumor DNA (ctDNA) in the blood—ignores a fundamental biological reality: not every "cancer" found by a high-sensitivity test needs to be found. By chasing the ghost of early detection, we are inviting a tidal wave of overdiagnosis, psychological trauma, and a financial collapse of a healthcare system already gasping for air. We are trading clinical outcomes for data points, and the cost will be measured in more than just pounds and pence.
The Tyranny of the False Positive
The logic of the NHS trial seems airtight on the surface. Find the cancer before symptoms appear, treat it, and save the patient. But this assumes that every cancerous cell detected is destined to kill. It isn't.
Biology is messy. Our bodies frequently develop microscopic malignancies that the immune system naturally surveils and destroys, or that simply grow so slowly they would never have caused a symptom within the patient's lifetime. This is the phenomenon of overdiagnosis. When you deploy a test as sensitive as a liquid biopsy across a healthy population, you aren't just finding "early cancer." You are finding biological noise.
Once that noise is labeled "cancer," the machine cannot be stopped. A positive blood test necessitates invasive follow-ups: CT scans, MRIs, biopsies, and often, preemptive surgery or toxic chemotherapies. We are currently on a collision course where we will "cure" thousands of people of diseases that never would have harmed them, while leaving them with the life-long side effects of unnecessary intervention.
The Sensitivity Paradox
Let’s look at the math that the "genuine hope" crowd ignores. In any screening program, the Positive Predictive Value (PPV) is what actually matters to the patient. If your test comes back positive, what are the actual odds you have the disease?
Even with a specificity of 99%, if you test 100,000 people for a cancer with a prevalence of 1%, you will generate roughly 1,000 true positives and 990 false positives. You have effectively flipped a coin with that patient's mental health. The NHS trial participants are being sold on the 99% accuracy of the technology, but they aren't being told about the 50/50 reality of their individual results.
The Infrastructure Mirage
Proponents of MCED tests speak as if the blood test is the finish line. It’s barely the starting blocks.
If the NHS successfully rolls out blood-based screening to the general public, the downstream "diagnostic bottleneck" will shift from a crawl to a total standstill. A positive ctDNA result does not tell a surgeon where to cut. It merely says "something is wrong." This triggers a diagnostic odyssey.
- Radiology Backlogs: Who performs the millions of additional scans required to confirm the location of these "early" signals?
- Biopsy Capacity: Pathologists are already overworked. An influx of asymptomatic "patients" will push wait times for symptomatic patients—those who actually need urgent care—into the months or years.
- The "Wait and See" Purgatory: What happens when a blood test is positive but the scans are clear? You have created a "pre-patient"—someone who is officially healthy but lives under the sword of Damocles, returning for scans every six months until a tumor finally grows large enough to be seen.
I have seen healthcare initiatives burn through billions because they focused on the "cool" diagnostic tool while ignoring the boring, physical infrastructure required to handle the results. The NHS is currently struggling to meet basic 62-day cancer targets for people who already have symptoms. Flooding the system with asymptomatic positives is not innovation; it is administrative arson.
The Mortality Fallacy
We must stop confusing "Five-Year Survival Rates" with "Saving Lives." This is the oldest trick in the epidemiological book, known as lead-time bias.
Imagine two patients, both destined to die of a specific cancer at age 70.
- Patient A is diagnosed at age 67 after feeling a lump. They die three years later. Their 5-year survival is 0%.
- Patient B gets a liquid biopsy at age 62. The cancer is detected. They live with the knowledge of their disease for eight years before dying at 70. Their 5-year survival is 100%.
In both cases, the patient died at the exact same time. The "early detection" didn't grant Patient B an extra second of life; it only granted them five extra years of being a "cancer patient." By shifting the date of diagnosis earlier without actually changing the date of death, we create the statistical illusion of progress while increasing the duration of patient suffering.
Unless these NHS trials can definitively prove a reduction in all-cause mortality, we are simply paying more to be sick longer.
Follow the Capital
Why is the push for liquid biopsy so relentless? Because it represents a shift from a "reactive" healthcare model to a "subscription" model.
In the reactive model, you treat the sick. In the MCED model, everyone is a potential customer, forever. These tests aren't meant to be taken once; they are designed for annual or bi-annual repetition. It is a massive transfer of public wealth to biotech firms under the guise of "prevention."
The cost-effectiveness models used to justify these trials are often wildly optimistic. They assume that early treatment is always cheaper than late-stage treatment. This ignores the cumulative cost of monitoring the thousands of false positives and treating the overdiagnosed. When you factor in the price of the tests themselves—which aren't cheap—the "savings" to the NHS vanish.
The Real Innovation We’re Ignoring
If we actually wanted to move the needle on cancer mortality, we wouldn't be looking for fragments of DNA in the blood of 50-year-olds. We would be addressing the systemic failures in the current diagnostic pathway.
- Symptomatic Speed: Reducing the time from "first symptom" to "first treatment" for known, aggressive cancers has a far greater impact on mortality than finding indolent tumors in healthy people.
- Primary Care Access: You don't need a multi-million-pound liquid biopsy if a patient can't get a GP appointment to discuss a persistent cough or a change in bowel habits.
- Prevention over Detection: We spend pennies on tobacco control, obesity, and environmental carcinogens compared to the fortunes we throw at high-tech detection.
The Ethics of the "Asymptomatic Patient"
We are fundamentally redefining what it means to be "healthy." Under the regime of liquid biopsies, health is no longer the absence of illness; it is merely the period between tests.
This creates a class of "worried well" that drains resources from the "actually ill." It prioritizes the person who can afford to navigate the private-public crossover of modern diagnostics over the person in a working-class community whose late-stage lung cancer is ignored until they end up in A&E.
The NHS trial isn't a "holy grail." It is a high-stakes gamble with our definitions of disease and our limited medical resources. We are being asked to cheer for a future where we are all patients, all the time, monitored by algorithms that can't distinguish between a lethal threat and a biological quirk.
Stop waiting for a blood test to save you. Demand a healthcare system that can actually treat you when you're sick, rather than one that spends its last pound trying to convince you that you might be.
Medicine has always been about the art of knowing when to intervene. Liquid biopsy is the science of intervening everywhere, all at once, regardless of the consequences.
The test might be "positive," but for the future of the NHS, the result looks devastatingly negative.
